Axogen, Inc. reported first quarter 2025 revenue of $48.56 million, an increase of 17% compared to $41.38 million in the first quarter of 2024. This growth reflects strong commercial execution and increased sales productivity.
The company's net loss for Q1 2025 improved to $3.83 million, or $0.08 per share, compared to a net loss of $6.64 million, or $0.15 per share, in the prior year period. This reduction in net loss indicates progress towards profitability.
Axogen maintained its full-year revenue growth guidance in the range of 15% to 17% and reiterated its gross margin expectation of 73% to 75%. This guidance includes a projected 1% impact on gross margin from one-time costs related to the anticipated Biologics License Application (BLA) approval.
The company also reaffirmed its expectation to be net cash flow positive for the full year 2025. These financial results and consistent guidance underscore Axogen's confidence in its strategic objectives and market development plans.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.